Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sonja M. Bragg"'
Autor:
Jennifer A. Zimmer, Sergey Shcherbinin, Michael D. Devous Sr., Sonja M. Bragg, Katherine J. Selzler, Alette M. Wessels, Craig Shering, Jamie Mullen, John Landry, Scott W. Andersen, AnnCatherine M. Downing, Adam S. Fleisher, Diana Otero Svaldi, John R. Sims
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic pla
Externí odkaz:
https://doaj.org/article/b11b2d19d9184e3eb390acfbb6efc91b
Autor:
Erin G Doty, Uwe Reuter, Sonja M. Bragg, Timothy Smith, Sherie A. Dowsett, Judith Krikke-Workel, Qun Lin, Messoud Ashina, Suzanne Klise, John H. Krege
Publikováno v:
Cephalalgia
Ashina, M, Reuter, U, Smith, T, Krikke-Workel, J, Klise, S R, Bragg, S, Doty, E G, Dowsett, S A, Lin, Q & Krege, J H 2021, ' Randomized, controlled trial of lasmiditan over four migraine attacks : Findings from the CENTURION study ', Cephalalgia, vol. 41, no. 3, pp. 294-304 . https://doi.org/10.1177/0333102421989232
Ashina, M, Reuter, U, Smith, T, Krikke-Workel, J, Klise, S R, Bragg, S, Doty, E G, Dowsett, S A, Lin, Q & Krege, J H 2021, ' Randomized, controlled trial of lasmiditan over four migraine attacks : Findings from the CENTURION study ', Cephalalgia, vol. 41, no. 3, pp. 294-304 . https://doi.org/10.1177/0333102421989232
Background We present findings from the multicenter, double-blind Phase 3 study, CENTURION. This study was designed to assess the efficacy of and consistency of response to lasmiditan in the acute treatment of migraine across four attacks. Methods Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6567ac8218687f8a6f9562e38684a92
https://doi.org/10.1177/0333102421989232
https://doi.org/10.1177/0333102421989232
Publikováno v:
Current medical research and opinion. 38(5)
The robust enrollment in SPARTAN and SAMURAI provided the opportunity to present post-hoc descriptive details on migraine disease characteristics and treatment outcomes after treatment with lasmiditan, a selective serotonin (5-HT1F) receptor agonist,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9916279bbd469dc21f29d590593fbbde
https://pubmed.ncbi.nlm.nih.gov/35350937
https://pubmed.ncbi.nlm.nih.gov/35350937
Autor:
John H. Krege, Sherie A. Dowsett, Todd J. Schwedt, P A Ardayfio, Sonja M. Bragg, Erin G Doty, Cristina Tassorelli, Dustin D. Ruff
Publikováno v:
The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Background Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment across 4 attacks (CENTURIO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4895543a4e2db623beed5bfdc3c5b544
http://europepmc.org/articles/PMC8572440
http://europepmc.org/articles/PMC8572440
Autor:
Diana O. Svaldi, Sergey Shcherbinin, Michael D. Devous, John R. Sims, John Landry, Sonja M. Bragg, Jamie Mullen, Jennifer A. Zimmer, Adam S. Fleisher, Alette M. Wessels, Scott W. Andersen, Katherine J. Selzler, Craig Shering, AnnCatherine M. Downing
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic plaque burde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30522ee60a1701be1c8c420063ec0a54
https://doi.org/10.1002/trc2.12123
https://doi.org/10.1002/trc2.12123
Autor:
Jamie Mullen, Sonja M. Bragg, Sharon Cohen, John Landry, Jennifer A. Zimmer, AnnCatherine M. Downing, Pierre N. Tariot, James H. Krull, Peter Barker, Scott W. Andersen, Sergey Shcherbinin, John R. Sims, Emer MacSweeney, Jennifer Schumi, Brandy R. Matthews, Alette M. Wessels, Robert S. Stern, Brian A. Willis, Katherine J. Selzler, Mercè Boada, Bruno Vellas, Craig Shering
Publikováno v:
JAMA Neurology. 77:199
Importance Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living. Current treatments provide only minor symptomatic improvements with limited benefit duration. Lanabece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50291f67ddb4a2e3b21e2b023d5a56e3
https://doi.org/10.1001/jamaneurol.2019.3988
https://doi.org/10.1001/jamaneurol.2019.3988